Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Patent Thicketing Has Cost US $7.6bn

Executive Summary

A recent study by the AAM’s Biosimilars Council has found that delayed access to biosimilars has cost the US healthcare system $7.6bn since 2015; meanwhile, Medicare has foregone more than $1.2bn in savings from biosimilars since 2015.

You may also be interested in...



AAM Urges Action On Product Hopping And Patent Thickets

The AAM’s senior vice-president, Jeffrey Francer, has offered suggestions to US lawmakers on how to curb anti-competitive tactics used by originators.

‘Perverse’ Tactics Cost US $10bn In Biosimilar Savings

The AAM’s Biosimilars Council has said “rebate traps” and other barriers to biosimilar adoption have cost the US healthcare system $2.2bn in lost savings since 2015. That’s on top of patent abuses which the council calculated in a June report have cost the healthcare system $7.6bn – bringing total lost savings from biosimilars to nearly $10bn.

Bruised Over Humira Patent Games, AbbVie Sees Smoother Road With Botox

AbbVie’s proposed acquisition of Allergan unites two companies that have gained notoriety for their exhaustive and unconventional efforts, respectively, to extend the patents of key products.

Related Content

Topics

UsernamePublicRestriction

Register

GB140487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel